Dual Time Point PET in Lymphoma

• Conditions: Hodgkin's and Non-Hodgkin's Lymphoma

• Registration Number: NCT01894945
• Lead Sponsor: Odense University Hospital

Brief Summary

This study aims to investigate the value of dual time point PET/CT in lymphoma. Since FDG uptake is linked to glucose metabolism, PET imaging is also used to detect suspected sites for infectious and inflammatory disorders. In a clinical setting, it is a challenge to distinguish between FDG uptake in benign and malignant lesions and this gives rise to a considerable quantity of false positive results and decreased positive predictive values. Performing FDG-PET imaging sixty minutes after injection is common practice in the staging and surveillance of lymphoma but this procedure may not be optimal, especially not in settings where benign inflammatory lesions are of clinical concern.

In an attempt to find an alternative method for this discrimination, dual time point FDG-PET was introduced. This technique has shown itself to be a potentially promising method in FDG-PET imaging for distinguishing between malignant and benign lesions using SUV values. The reason for the different FDG uptake patterns between inflammatory and malignant lesions is unclear. Several factors may contribute to this phenomenon on a cellular basis. It has been shown that cancer cells exhibit increased numbers of glucose transporter and low level of glucose-6-phosphatase. Varying levels between different cancer cell types may explain the different FDG uptake curves. Because various cell types exhibit varying rates of FDG uptake we believe that kinetic investigation may prove to be of value in understanding different types of lymphoma and identifying how to perform precise imaging for staging and surveillance.

Detailed Description

Not available

Study Timeline

• Study Start: 2012-03
• Status Verified: 2013-07
• Study First Submitted: 2013-07-04
• Study First Submitted QC: 2013-07-09
• Last Update Submitted: 2013-07-09
• Study First Posted: 2013-07-10
• Last Update Posted: 2013-07-10
• Primary Completion: 2014-02
• Study Completion: 2014-07

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

• Age>18 years
• Planned for curative treatment

Exclusion Criteria

• Previously treatment with chemotherapy or irradiation
• Primary CNS lymphoma
• Recurrent lymphoma
• Transformation from indolent lymphoma
• Presence of diabetes mellitus, HIV, chronic inflammatory disease or infections
• Pregnancy or lactation

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Progression Free Survival	2 years	To evaluate the predictive value of PET after 60min compared to PET after 180min in terms of outcome.
Progression free survival	3 years	To evaluate the predictive value of PET after 60min compared to PET after 180min in terms of outcome.

Secondary Outcome Measures

Name	Time	Method
Overall survival	2 years, 3 years	To evaluate the predictive value of PET after 60min compared to PET after 180min in terms of outcome.

Trial Locations

Locations (2)

Odense University Hospital, Department of hematology; 🇩🇰 Odense, Denmark

Roskilde Hospital; 🇩🇰 Roskilde, Denmark